These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

600 related items for PubMed ID: 17172711

  • 1. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C, Pei J, Kumar D, Sakabe I, Boudreau HE, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [Abstract] [Full Text] [Related]

  • 2. Systemic delivery and pre-clinical evaluation of nanoparticles containing antisense oligonucleotides and siRNAs.
    Zhang C, Newsome JT, Mewani R, Pei J, Gokhale PC, Kasid UN.
    Methods Mol Biol; 2009; 480():65-83. PubMed ID: 19085118
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, toxicity, and efficacy of ends-modified raf antisense oligodeoxyribonucleotide encapsulated in a novel cationic liposome.
    Gokhale PC, Zhang C, Newsome JT, Pei J, Ahmad I, Rahman A, Dritschilo A, Kasid UN.
    Clin Cancer Res; 2002 Nov; 8(11):3611-21. PubMed ID: 12429653
    [Abstract] [Full Text] [Related]

  • 4. Combination bcl-2 antisense and radiation therapy for nasopharyngeal cancer.
    Yip KW, Mocanu JD, Au PY, Sleep GT, Huang D, Busson P, Yeh WC, Gilbert R, O'Sullivan B, Gullane P, Bastianutto C, Liu FF.
    Clin Cancer Res; 2005 Nov 15; 11(22):8131-44. PubMed ID: 16299246
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies.
    Dritschilo A, Huang CH, Rudin CM, Marshall J, Collins B, Dul JL, Zhang C, Kumar D, Gokhale PC, Ahmad A, Ahmad I, Sherman JW, Kasid UN.
    Clin Cancer Res; 2006 Feb 15; 12(4):1251-9. PubMed ID: 16489081
    [Abstract] [Full Text] [Related]

  • 6. Tumor regression by combination antisense therapy against Plk1 and Bcl-2.
    Elez R, Piiper A, Kronenberger B, Kock M, Brendel M, Hermann E, Pliquett U, Neumann E, Zeuzem S.
    Oncogene; 2003 Jan 09; 22(1):69-80. PubMed ID: 12527909
    [Abstract] [Full Text] [Related]

  • 7. Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
    Mewani RR, Tang W, Rahman A, Dritschilo A, Ahmad I, Kasid UN, Gokhale PC.
    Int J Oncol; 2004 May 09; 24(5):1181-8. PubMed ID: 15067340
    [Abstract] [Full Text] [Related]

  • 8. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
    Holmlund JT, Monia BP, Kwoh TJ, Dorr FA.
    Curr Opin Mol Ther; 1999 Jun 09; 1(3):372-85. PubMed ID: 11713802
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of BCL-2 in small cell lung cancer cell lines with oblimersen, an antisense BCL-2 oligodeoxynucleotide (ODN): in vitro and in vivo enhancement of radiation response.
    Loriot Y, Mordant P, Brown BD, Bourhis J, Soria JC, Deutsch E.
    Anticancer Res; 2010 Oct 09; 30(10):3869-78. PubMed ID: 21036697
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.
    Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B.
    Biomaterials; 2008 Oct 09; 29(29):4022-8. PubMed ID: 18653231
    [Abstract] [Full Text] [Related]

  • 15. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT, Parkinson DR.
    Semin Oncol; 1997 Apr 09; 24(2):187-202. PubMed ID: 9129689
    [Abstract] [Full Text] [Related]

  • 16. c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligodeoxynucleotide ISIS 5132 (CGP 69846A).
    O'Dwyer PJ, Stevenson JP, Gallagher M, Cassella A, Vasilevskaya I, Monia BP, Holmlund J, Dorr FA, Yao KS.
    Clin Cancer Res; 1999 Dec 09; 5(12):3977-82. PubMed ID: 10632328
    [Abstract] [Full Text] [Related]

  • 17. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 09; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
    Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D.
    Nat Med; 1996 Jun 09; 2(6):668-75. PubMed ID: 8640558
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.